India PesticidesQ1 FY26

India Pesticides Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹116.27P/E: 14.2Market Cap: ₹1.3K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • FY26 revenue target set at Rs. 1,000 crores with 18%-20% EBITDA margin (Page 5-6).
  • Growth of 15%-20% expected in FY27 in revenue with EBITDA margins maintained between 18%-20% (Page 11).
  • Expansion of PEDA intermediate capacity from 2,000 to 8,500 tons/year to drive sales growth; Rs. 150 crores revenue expected from PEDA and Pretilachlor combined in FY26, rising to Rs. 250-300 crores in FY27 (Page 11-13, 16).
  • Hamirpur plant to contribute Rs. 100 crores revenue in FY26-27; full potential of Rs. 1,000-1,100 crores achievable in 3-4 years with Rs. 400-500 crores incremental capex (Page 15).
  • New product launches and backward integration to enhance margins and diversify portfolio (Page 5, 13).
  • Export order book showing growth with stable pricing except some pressure in Prosulfocarb; formulation and technical segments expected to grow in line with domestic and export demand (Page 8-9, 16).

See what India Pesticides management said on margin guidance — free account, 30 seconds.

Fundraise plans

- No explicit mention of new fundraising through debt or equity in the call transcript. - The company plans to fund its Capex primarily through internal accruals. - Current Capex planned is Rs. 116 crores for FY26 (Rs. 52 crores at existing site and Rs. 64 crores at Hamirpur subsidiary). - CFO mentioned reduction in interest cost going forward due to liquidation of inventory and lower working capital borrowings. - No indication of fresh debt or equity issuance discussed during the Q&A or management commentary. Summary: India Pesticides Ltd. intends to fund expansion and Capex needs largely via internal cash flows and does not indicate any current or planned external fundraising through debt or equity.

See what India Pesticides management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Total planned Capex for FY 26 is Rs. 116 crores, split as:
  • - Rs. 52 crores for existing manufacturing facilities.
  • - Rs. 64 crores for Hamirpur site (wholly owned subsidiary Shalvis Specialties Ltd).
  • Hamirpur site is a greenfield project on 25 acres, aimed to eventually generate Rs. 1,000-1,100 crores revenue in 3-4 years.
  • Current Capex at Hamirpur is Rs. 64 crores this year, with Rs. 400-500 crores more expected to fully realize growth potential.
  • Capex aimed at capacity expansion, new product additions, and enhancing operational efficiency.
  • Plans for expansion include increasing PEDA intermediate facility capacity from 2,000 to 6,000 tons per annum, targeting 8,500 tons in Q2 FY 26.
  • Strategy is to fuel Capex primarily with internal accruals to support profitable growth and self-reliant manufacturing.

Track India Pesticides — get its next earnings analysis in your feed

How does India Pesticides rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisIndia Pesticides
Rev 3Mar 3

How does India Pesticides rank in Fertilizers & Agrochemicals?

Compare India Pesticides against every Fertilizers & Agrochemicals company (Q1 FY26) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →